Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Therapy for Advanced Liver Cancer
NCT06084299Phase 1Recruiting
- Start
- May 2020
- Primary completion
- Aug 2026
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tumor-infiltrating lymphocytes in liver cancer. Primary endpoints: Dose-limiting toxicity at 1 month, Adverse Events and Serious Adverse Events up to 24 months and 1 more. Started May 2020; status: recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT06084299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06084299.